Skip to content
TubeRank.
Get app
HIMS

The call, on record

HIMS bullish call

Recorded from Asymmetric Investing by Travis Hoium’s public commentary. Review the evidence behind the call and its outcome.
HIMSBullNot scored
Asymmetric Investing by Travis HoiumAsymmetric Investing by Travis Hoium
AI-extracted record · awaiting moderator review. The quote is source evidence; the structured call and thesis are TubeRank’s interpretation.
Quoted text as recorded“Hims and Hers is one of the biggest positions, actually the biggest position today in that portfolio.”

Our interpretation

Source published
Sep 1, 2026
Interpreted confidence
high
Specificity
vague

Why this call is unscored

Status
Not scored
Notes
There is no numerical target that can be objectively scored.

How outcomes are decided · Report an error

Email me when HIMS calls resolve

When a tracked HIMS call is scored — hit, miss or partial — we’ll email you the result. No account needed.

Used only for these updates. Privacy

Follow Asymmetric Investing by Travis Hoium in the iPhone appEvery HIMS call on file

Evidence and source

The Hims & Hers Australia Strategy: Why It Matters for Investors
Published on Sep 1, 2026Open on YouTube

Our summary of the thesis

Strongly Bullish

Structured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.

Travis argues Hims & Hers is executing a long-term strategy to become a single, unified global healthcare brand (akin to Netflix or Uber), unifying its Hims/Hers branding, tech stack, and pharma deals across countries following acquisitions like Eucalyptus. He sees the recent Australia rebrand as symbolic of a much larger opportunity to become the dominant global aggregator of healthcare demand, driving subscriber growth, rising revenue per subscriber, and eventually a much higher valuation.

Key arguments

  • Unifying disparate international brands (like Pilot in Australia) into one global 'Hims' brand mirrors the playbook of Netflix, Uber, Google, and Facebook.
  • Subscribers have grown from ~600,000 at the end of 2021 to 2.9 million currently, boosted by the Eucalyptus acquisition and branded weight-loss products.
  • Monthly revenue per subscriber has risen from $59 to $92 and could reach at least $300 as more branded solutions, labs, and services are added.
  • The combination of subscriber growth and rising spend per subscriber supports a ~55% revenue CAGR, with 2026 guidance implying over 50% growth in the second half of the year.
  • Becoming a single global brand and unified tech stack makes the business more efficient and scalable long-term, positioning it as an 'aggregator of demand' in healthcare.

Counter-arguments acknowledged

  • The stock has been volatile, falling as much as 50% at one point due to market concerns.
  • The company is not yet profitable, and it's unclear when operating profit and net income will improve.
  • Integrating tech stacks and branding across countries will take time.

Hedges and caveats (from the video)

  • Stock has experienced significant volatility (down 50% at some point)
  • Integration of acquisitions and unified tech stack will take time
  • Long-term vision required; near-term execution risks exist
  • Analyst holds HIMS as largest position in personal portfolio (potential bias)

About this record

Not yet reviewed by a moderator

AI-extracted record. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.

Source published
Sep 1, 2026, 5:42 PM UTC
First recorded by TubeRank
Sep 1, 2026, 6:21 PM UTC
Record last updated
Oct 6, 2026, 6:32 AM UTC
Moderator review recorded
Not recorded
Transcript provenance
YouTube captions (manual or automatic)
Recorded analysis processor/source label
claude-sonnet-5
This can identify a workflow rather than an exact AI model version.
Extraction pipeline version
v1.0.0
Outcome methodology version
2026-10-06.5
Outcome reason code
missing_target
Publication is when the video was released; recording is when TubeRank added this call. They are not interchangeable. Legacy records can lack version and observation metadata. Dates are shown in UTC.
Recent record changes 4 shown

  1. Oct 6, 2026, 6:32 AM UTC

    corrected

    Outcome methodology version

    Before2026-10-06.4

    After2026-10-06.5

  2. Oct 6, 2026, 5:14 AM UTC

    corrected

    Outcome methodology version

    Before2026-10-06.2

    After2026-10-06.4

  3. Oct 6, 2026, 4:01 AM UTC

    corrected

    Outcome methodology version

    Before2026-10-06.1

    After2026-10-06.2

  4. Oct 6, 2026, 3:27 AM UTC

    missing target

    Outcome methodology version

    BeforeNot recorded

    After2026-10-06.1

    Recorded outcome date

    BeforeNot recorded

    After2026-10-06

    Outcome explanation

    BeforeNot recorded

    AfterThere is no numerical target that can be objectively scored.

    Outcome reason

    BeforeNot recorded

    AfterMissing target

Showing up to 20 recent changes. The complete feed has 5 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.

Methodology and limitationsReport a correction
Stored outcome evidence
Stored reference price
Not recorded
Not recorded · provider not recorded
Target as extracted
Not recorded
Stated deadline as extracted
None recorded
Recorded outcome date
Oct 6, 2026
Outcome price observation
Not recorded
Not recorded · provider not recorded

Stored explanation

There is no numerical target that can be objectively scored.

Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.

Why we interpreted the confidence this way

Personal stake signal (largest portfolio position) indicates strong conviction, though no specific price target is given.

View full video analysisView YouTuber profile